Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Hepion Pharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on the development of therapeutics for chronic liver diseases. The company primarily operates within the biotechnology and pharmaceutical research industries, with an emphasis on liver fibrosis, cirrhosis, and nonalcoholic steatohepatitis (NASH). Hepion does not currently generate commercial product revenue and is primarily funded through equity financing and, historically, public capital markets.
The company’s core development program has centered on rencofilstat (also known as CRV431), a cyclophilin inhibitor evaluated for liver disease indications. Hepion positions itself as targeting upstream drivers of liver disease progression, differentiating its approach from therapies focused solely on metabolic or inflammatory pathways. The company traces its origins to ContraVir Pharmaceuticals, which was founded in 2007 and later rebranded as Hepion Pharmaceuticals, Inc. in 2019 to reflect its strategic shift toward liver disease therapeutics.
Business Operations
Hepion’s operations have historically consisted of a single operating segment focused on drug discovery and clinical development. Its primary asset has been rencofilstat, which advanced through Phase 2 clinical evaluation for NASH and liver fibrosis prior to development interruptions. The company’s business model is centered on advancing drug candidates through clinical proof-of-concept, with the long-term objective of licensing, partnering, or acquisition by larger pharmaceutical companies.
Operational activities have been conducted primarily in the United States, with clinical trials utilizing third-party contract research organizations. Hepion does not maintain manufacturing facilities and relies on external partners for clinical supply, regulatory support, and research services. As of the most recent public disclosures, development activities have been significantly constrained due to capital limitations, and certain programs have been paused. Data inconclusive based on available public sources regarding the current operational status of active clinical trials.
Strategic Position & Investments
Hepion’s stated strategic direction has been to focus resources on liver disease indications with high unmet medical need, particularly NASH and fibrosis. The company has previously invested the majority of its capital into clinical development of rencofilstat and related intellectual property. No material acquisitions have been completed in recent years, and Hepion has not reported a diversified portfolio of subsidiaries or late-stage pipeline assets.
Public filings indicate that the company has explored strategic alternatives, including potential partnerships, asset sales, or other corporate transactions, in response to liquidity challenges. While Hepion has positioned cyclophilin inhibition as a promising therapeutic approach, continued investment in emerging technologies or expanded indications has been limited by financial constraints. Data inconclusive based on available public sources regarding future investment commitments.
Geographic Footprint
Hepion Pharmaceuticals, Inc. is headquartered in the United States, with its corporate offices historically located in New Jersey. The company’s operational footprint is primarily domestic, with limited physical infrastructure and no international offices reported in recent filings.
International exposure has occurred mainly through clinical trial sites and service providers located outside the United States, depending on study design. Hepion does not report significant foreign revenue, international manufacturing, or direct commercial presence in other regions. Its global influence remains limited relative to larger multinational biopharmaceutical companies.
Leadership & Governance
Hepion is governed by a board of directors and managed by an executive team with experience in biotechnology, drug development, and public company governance. Leadership has emphasized scientific rigor, capital discipline, and strategic optionality in navigating the competitive and capital-intensive liver disease therapeutic landscape.
Key executives and leaders reported in recent public disclosures include:
- Robert Foster – President and Chief Executive Officer
- David Hagopian – Chief Financial Officer
- Christopher McHutchison – Chief Scientific Officer
- Diana L. Schneider – Director
Leadership philosophy has focused on advancing differentiated science while actively evaluating strategic alternatives to maximize shareholder value under constrained market conditions.